TY - JOUR T1 - Clinical practice guidelines and recommendations in the context of the COVID-19 pandemic: systematic review and critical appraisal JF - medRxiv DO - 10.1101/2020.06.19.20134767 SP - 2020.06.19.20134767 AU - Tanja A Stamm AU - Margaret R Andrews AU - Erika Mosor AU - Valentin Ritschl AU - Linda C Li AU - Jasmin K Ma AU - Adalberto Campo Arias AU - Sarah Baker AU - Nicola W Burton AU - Mohammad Eghbali AU - Natalia Fernandez AU - Ricardo Ferreira AU - Gabriele Gäbler AU - Souzi Makri AU - Sandra Mintz AU - Rikke Moe AU - Elizabeth Morasso AU - Susan L Murphy AU - Simiso Ntuli AU - Maisa Omara AU - Miguel Angel Simancas Pallares AU - Jen Horonieff AU - Gerald Gartlehner Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/20/2020.06.19.20134767.abstract N2 - Background The number of published clinical practice guidelines and recommendations related to SARS-CoV-2 infections causing COVID-19 has rapidly increased. However, insufficient consideration of appropriate methodologies in the guideline development could lead to misleading information, uncertainty among professionals, and potentially harmful actions for patients.Purpose Rapid systematic review of clinical practice guidelines and recommendations in the context of COVID-19 to explore if basic methodological standards of guideline development have been met.Data sources MEDLINE [PubMed], CINAHL [Ebsco], Trip and manual search; from Feb 1st 2020 until April 27th 2020.Study selection All types of healthcare workers providing any kind of healthcare to any patient population in any setting.Data extraction At least two reviewers independently extracted guideline characteristics, conducted critical appraisal according to The Appraisal of Guidelines for Research and Evaluation Instrument (AGREE II) and classified the guidelines using the Association of the Scientific Medical Societies (AWMF) Guidance Manual and Rules for Guideline Development. We plan six-month updates (living review).Data synthesis There were 1342 titles screened and 188 guidelines included. The highest average AGREE II domain score was 89% for scope and purpose, the lowest for rigor of development (25%). Only eight guidelines (4%) were based on a systematic literature search and a structured consensus process by representative experts (classified as the highest methodological quality, S3 according to AWMF). Patients were only included in the development of one guideline. A process for regular updates was described in 27 guidelines (14%).Limitations Methodological focus only.Conclusions Despite clear scope, most publications fell short of basic methodological standards of guideline development. Future research should monitor the evolving methodological quality of the guidelines and their updates over time.Registration/Publication The protocol was published at www.researchgate.net, DOI: 10.13140/RG.2.2.21293.51689. Preliminary results are publicly available on medRxiv.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://www.researchgate.net/publication/341670661_Clinical_practice_guidelines_and_recommendations_in_the_context_of_the_COVID-19_pandemic_systematic_review_and_critical_appraisal Funding StatementFunding Source: This study was partly funded by the COVID-19 Rapid Response Funding Scheme of the Wiener Wissenschafts-, Forschungs- und Technologiefonds (WWTF)/Vienna Science and Technology Fund (project number COV20-028). The funding institution had no influence on the results of this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicable.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are published as supplemental files. ER -